Origins is the global patient focused specialist consultancy that provides industry-leading insights and strategic counsel for our clients at critical decision points in drug development and commercialisation. To learn more, please visit www.origins-patients.com

NeoGenomics specializes in premier cancer solutions. We partner with pharmaceutical clients from discovery to commercialization with our broad oncology testing capabilities powered by in-house scientific expertise and dedicated project support teams. Our clients benefit from our state-of-the-art molecular technology, from whole exome sequencing, whole transcriptome sequencing, HLA typing, and the proprietary MultiOmyx™ high-order multiplexing methodology. We are the trusted experts with over 20 years of experience helping navigate the increasingly complex cancer landscape. For more information, visit https://neogenomics.com.

STEMCELL Technologies provides extensive cell culture and isolation tools for stem cell and immunology research. Driven by science and a passion for quality, STEMCELL Technologies manufactures products for immune cell isolation, activation, and expansion to advance cancer research and immunotherapy development. For more information, visit https://www.stemcell.com/

PhaseV is a technology company leveraging advanced causal inference and machine learning to innovate clinical trials. Our technology and methods enable us to optimize trial design by detecting hidden signals in existing clinical data and extracting actionable insights, as well as supporting advanced adaptive designs for more efficient, precise and successful clinical trials. For more information, please visit https://phasevtrials.com/

Aixial is a global, therapeutically focused Clinical Research Organization with extensive expertise in the immuno-oncology therapeutic area. Since 2002, the company has been a trusted partner in the rapidly evolving immuno-oncology field.

Aixial’s team is experienced in managing the complexities of immuno-oncology trials, from Phase I first in human through post marketing.  By offering flexible clinical trial services we accelerate development by augmenting client teams with experts, enabling robust clinical outcomes, and helping clients navigate the challenges of bringing new cancer therapies to market. For more information, visit https://www.aixialgroup.com/

Standard BioTools delivers the leading omics solutions that empower life sciences researchers to discover unique biological insights not accessible by other technologies. Our high-content platforms in affinity-based, spatial and single-cell proteomics and multi-omics offer the highest levels of precision and unique scalability in the life sciences industry. Integration of highly multiplexed single-cell proteomics using CyTOF™ technology with the plasma-based and spatial proteomic modalities of SomaScan™ and Hyperion™ platforms provides characterization of multiple interconnected biological systems and their interactions, leading to a deeper understanding of response and discovery of critical biomarkers that together can form highly predictive signatures. For more information, visit https://www.standardbio.com/

One2Treat is a forward-thinking partner for biopharmaceutical companies, dedicated to delivering transformative insights in clinical trial design, analysis, and market access evaluations to support holistic treatment decisions.

Driven by a commitment to patient-centricity, One2Treat leverages modern statistical methodologies and advanced software solutions, ushering in a new era of personalized healthcare. For more information, please visit https://one2treat.com/

Champions Oncology is a global preclinical research and clinical specialty testing services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Champions is a fully regulated clinical laboratory that can validate assays to GCLP compliance with CAP accreditation and CLIA certification. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide.  For more information, please visit www.ChampionsOncology.com.

For more information, please visit https://www.klick.com/

Cerba Research Canada (Cerba), formerly CIRION, is a bioanalytical and biomarker testing laboratory that has been operating since 2001. A fully regulated laboratory that can validate assays to GLP/GCLP, as well as CAP/CLIA standards. Focused on biologics programs, Cerba has deep experience developing and validating PK, ADA, nAb, and soluble biomarker assays using ligand binding and cell-based assays, as well as molecular testing using qPCR. For more information, visit https://cerbaresearch.com/

Headquartered in New Jersey, BeyondSpring Inc. is dedicated to raising the standard of care for cancer patients by developing first-in-class treatments that enhance lives and clinical outcomes for millions of patients in need. Its lead asset plinabulin is a first-in-class selective immunomodulating microtubule-binding agent with dendritic cell maturation activity.  With over 700 cancer patients treated, Plinabulin is being developed as a “pipeline in a drug” for multiple cancer indications with severe unmet medical needs, including extended stage SCLC and metastatic NSCLC with no driver mutation and progressed on prior PD-(L)1 inhibitors. For more information, visit https://beyondspringpharma.com/

To learn more, please visit https://www.jnj.com/